Clinical trial NCT00043368: PF-3512676 (CPG 7909) Injection For Patients Who Completed An Oncology Study Using PF-3512676 (CPG 7909)
Official title: A Continuation Study Of PF-3512676 (CPG 7909) Injection In Patients With Metastatic Or Recurrent Malignancies Who Have Stable Disease Or Who Have Responded To Pf-3512676 Injection Therapy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Melanoma
Breast Neoplasms
Carcinoma, Renal Cell
Lymphoma, T-Cell
Carcinoma, Non-Small-Cell Lung
Keywords: CPG 7909 continuation study
Lead sponsor: Pfizer
Sponsor class: INDUSTRY
First posted: 2002-08-12
Enrollment: 31
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This protocol allows patients who completed Coley oncology studies using PF-3512676 (CPG 7909) Injection to continue receiving the treatment until disease progression.


Eligibility criteria: Inclusion Criteria:

Immediate (within 4 weeks) prior completion of a clinical trial of PF-3512676 Injection alone or in combination with other anti-neoplastic treatment for malignancy.

Exclusion Criteria:

The patient has received any anti-neoplastic therapy since completing a prior trial with PF-3512676 Injection, or has participated in another clinical trial following participation in a trial with PF-3512676 Injection.

Primary outcomes:
measure: Adverse Events and DLTs will be evaluated by the Investigator and summarized.
timeFrame: indeterminate
Secondary outcomes:
measure: No formal statistical analysis of this study will be conducted. All clinical data may be summarized and included in data listings.
timeFrame: indeterminate
Other outcomes:
Locations:
city: Berkely
country: United States
facility: Pfizer Investigational Site
state: California
city: Gilroy
country: United States
facility: Pfizer Investigational Site
state: California
city: Hollister
country: United States
facility: Pfizer Investigational Site
state: California
city: Los Angeles
country: United States
facility: Pfizer Investigational Site
state: California
city: Los Angeles
country: United States
facility: Pfizer Investigational Site
state: California
city: Palm Springs
country: United States
facility: Pfizer Investigational Site
state: California
city: Stanford
country: United States
facility: Pfizer Investigational Site
state: California
city: New Haven
country: United States
facility: Pfizer Investigational Site
state: Connecticut
city: Bonita Springs
country: United States
facility: Pfizer Investigational Site
state: Florida
city: Bradenton
country: United States
facility: Pfizer Investigational Site
state: Florida
city: Cape Coral
country: United States
facility: Pfizer Investigational Site
state: Florida
city: Fort Myers
country: United States
facility: Pfizer Investigational Site
state: Florida
city: Fort Myers
country: United States
facility: Pfizer Investigational Site
state: Florida
city: Naples
country: United States
facility: Pfizer Investigational Site
state: Florida
city: Plantation
country: United States
facility: Pfizer Investigational Site
state: Florida
city: Port Charlotte
country: United States
facility: Pfizer Investigational Site
state: Florida
city: Sarasota
country: United States
facility: Pfizer Investigational Site
state: Florida
city: Venice
country: United States
facility: Pfizer Investigational Site
state: Florida
city: Venice
country: United States
facility: Pfizer Investigational Site
state: Florida
city: Chicago
country: United States
facility: Pfizer Investigational Site
state: Illinois
city: Chicago
country: United States
facility: Pfizer Investigational Site
state: Illinois
city: Vincennes
country: United States
facility: Pfizer Investigational Site
state: Indiana
city: Ann Arbor
country: United States
facility: Pfizer Investigational Site
state: Michigan
city: Olive Branch
country: United States
facility: Pfizer Investigational Site
state: Mississippi
city: Oxford
country: United States
facility: Pfizer Investigational Site
state: Mississippi
city: Livingston
country: United States
facility: Pfizer Investigational Site
state: New Jersey
city: Asheville
country: United States
facility: Pfizer Investigational Site
state: North Carolina
city: Portland
country: United States
facility: Pfizer Investigational Site
state: Oregon
city: Collierville
country: United States
facility: Pfizer Investigational Site
state: Tennessee
city: Memphis
country: United States
facility: Pfizer Investigational Site
state: Tennessee
city: Memphis
country: United States
facility: Pfizer Investigational Site
state: Tennessee
city: Koeln
country: Germany
facility: Pfizer Investigational Site
Study officials:
affiliation: Pfizer
name: Pfizer CT.gov Call Center
role: STUDY_DIRECTOR
References: